Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Short Interest Down 26.7% in January

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) saw a large drop in short interest in January. As of January 15th, there was short interest totaling 13,222 shares, a drop of 26.7% from the December 31st total of 18,047 shares. Based on an average daily trading volume, of 59,945 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.2% of the company’s shares are sold short. Approximately 0.2% of the company’s shares are sold short. Based on an average daily trading volume, of 59,945 shares, the days-to-cover ratio is currently 0.2 days.

Chemomab Therapeutics Stock Down 1.3%

CMMB traded down $0.02 on Friday, hitting $1.55. 22,134 shares of the company traded hands, compared to its average volume of 55,769. The company has a 50 day moving average of $2.00 and a 200-day moving average of $2.82. The stock has a market capitalization of $9.55 million, a PE ratio of -0.52 and a beta of 0.56. Chemomab Therapeutics has a 12-month low of $1.53 and a 12-month high of $8.76.

Wall Street Analyst Weigh In

CMMB has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Chemomab Therapeutics to a “hold” rating in a report on Saturday, October 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Chemomab Therapeutics in a report on Monday, December 29th. Finally, Zacks Research lowered shares of Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Chemomab Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $26.50.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC acquired a new position in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 51,710 shares of the company’s stock, valued at approximately $85,000. Kestra Private Wealth Services LLC owned 0.84% of Chemomab Therapeutics as of its most recent SEC filing. Institutional investors own 46.05% of the company’s stock.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.